The European Academy of Dermatology and Venereology (EADV) Congress 2024 will feature a groundbreaking study that provides the first scientific validation of a previously unproven connection. This research, which has been eagerly anticipated by the dermatology and venereology communities, promises to reshape our understanding of skin and sexual health.
The study aimed to investigate the effects of the anti-inflammatory drug, indomethacin, on these lesions. The results showed that indomethacin significantly reduced the severity of psoriatic lesions. The study suggests that indomethacin could be a potential therapeutic agent for psoriasis.
Further analysis showed that sonic stress significantly increased immune cell presence in the skin and elevated proinflammatory mediators like CXCL10, IL-22, IL-15, IL-17A/F, IFN-γ, and TNFα. Additionally, neurogenic inflammation biomarkers, such as nerve growth factor (NGF) and substance P (SP), were upregulated. Sonic stress also led to elevated levels of tryptase, indicating mast cell activation, and increased expression of NK-1R, the receptor for SP. “Psychoemotional stress triggers the release of proinflammatory neuropeptides like SP, leading to neurogenic skin inflammation by activating immune cells, particularly through mast cell degranulation,” explains Professor Amos Gilhar, lead researcher from the Skin Research Laboratory, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
The study suggests that NK1-R antagonists could be a promising treatment for preventing relapse in patients with relapsing-remitting MS. The research team’s investigation into the potential of NK1-R antagonists, specifically aprepitant, as a treatment for relapsing-remitting multiple sclerosis (MS) has yielded promising results.
He believes that understanding this connection could lead to significant advancements in psoriasis treatment. The research indicates that dysregulation in the nervous system may contribute to the development and exacerbation of psoriasis.
More information: Keren, A., Zeltzer, A. A., Bertolini, M., Paus, R., & Gilhar, A. (2024). Psoriatic lesions in human skin xenotransplants in vivo are triggered by perceived stress and can be suppressed by the neurokinin-1 receptor antagonist aprepitant. Presented at European Academy of Dermatology and Venereology (EADV) Congress 2024. Provided by European Academy of Dermatology and Venereology
news is a contributor at WhySkin. We are committed to providing well-researched, accurate, and valuable content to our readers.
